Fortress Biotech, Inc. FBIO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -47.54%
- 1 year
- -25.29%
- Open
- 2.01
- Prev close
- 2.00
- Mkt cap
- 64.03M
- Vol
- 196.84K
- Avg vol
- 410.92K
- EPS
- 2.76
- P/E
- 0.70
- Div yield
- 0.00%
More statistics
- Low
- 1.89
- High
- 2.01
- Forward P/E
- -0.99
- Beta
- 1.75
- Short ratio
- 4.57
- Inst. own
- 15.78%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.83
- 200-d avg
- 1.84
- 1y target
- 14.33
5D chart
Signals (50)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 12:40 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:25 PM | 1 day ago |
| RSI: Oversold | Oct 30, 12:25 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 1 day ago |
| RSI: Oversold | Oct 30, 11:25 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 1 day ago |
| RSI: Oversold | Oct 30, 10:20 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:00 AM | 1 day ago |
| RSI: Oversold | Oct 30, 10:00 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:35 AM | 1 day ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 2 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:15 AM | 2 days ago |
| RSI: Overbought | Oct 29, 11:00 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:40 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 3 days ago |
| RSI: Oversold | Oct 28, 3:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:20 AM | 3 days ago |
| RSI: Overbought | Oct 28, 11:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:25 PM | 4 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 26, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:45 PM | 5 days ago |
Key statistics
- Market cap
- 48.03M
- Enterprise value
- 12.37M
- Trailing P/E
- 0.00
- Forward P/E
- -0.99
- PEG ratio
- 0.00
- Price / sales
- 0.58
- Price / book
- 1.17
- EPS (TTM)
- -2.96
- Beta
- 1.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -49.25%
- Revenue (TTM)
- 82.62M
- Revenue growth
- -14.30%
- Free cash flow
- -59.20M
- Total cash
- 76.20M
- Total debt
- 88.42M
- Return on equity
- 0.00%
- Shares outstanding
- 27.60M
- Short % of float
- 11.50%
- 50-day average
- 1.83
- 200-day average
- 1.84
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 14.33
- Target (high)
- 24.00
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.27 | -0.76 | -0.49 | -181.48% |
| Aug 13, 2024 | Jun 1, 2024 | -1.32 | -0.73 | +0.59 | +44.70% |
| May 15, 2024 | Mar 1, 2024 | -2.03 | -1.03 | +1.00 | +49.26% |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -0.53 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -3.53 | -0.94 | +2.59 | +73.37% |
| Aug 14, 2023 | Jun 1, 2023 | -3.90 | -3.60 | +0.30 | +7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 20, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| May 16, 2024 | Roth MKM | reit | Buy | Buy |
| Mar 19, 2024 | Alliance Global Partners | init | — | Buy |
| Nov 29, 2023 | Roth MKM | main | Buy | Buy |
About Fortress Biotech, Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fortressbiotech.com
News
- Johnson & Johnson (NYSE:JNJ) vs. Fortress Biotech (NASDAQ:FBIO) Head to Head Review
- Contrasting RYTHM (NASDAQ:RYM) and Fortress Biotech (NASDAQ:FBIO)
- Journey Medical Corporation to Participate in September 2026 Investor Conferences
- Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)
- Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad
Your note
Sign in to keep a note on FBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HARVEY JIMMIE | Director | Stock Award(Grant) | Dec 28, 2023 | 69,999 |
| HOENLEIN MALCOLM | Director | Stock Award(Grant) | Dec 28, 2023 | 39,042 |
| JIN DAVID | Chief Financial Officer | Stock Award(Grant) | Sep 30, 2024 | 240,893 |
| KLEIN DOV | Director | Sale | May 19, 2024 | 53,400 |
| LOBELL JONAH JAY | Director | Stock Award(Grant) | Dec 28, 2023 | 115,692 |
| LORENZ KEVIN R. | Director | Stock Award(Grant) | Dec 28, 2023 | 24,970 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.26% | 625,054 | 1.09M | Sep 29, 2024 |
| Cambridge Investment Research Advisors Inc. | 2.01% | 554,400 | 964.66K | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 1.82% | 502,828 | 874.92K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.75% | 482,595 | 839.72K | Sep 29, 2024 |
| Shikiar Asset Management, Inc. | 0.85% | 235,969 | 410.59K | Sep 29, 2024 |
| Envestnet Asset Management | 0.67% | 183,946 | 320.07K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.70% | 470,544 | 818.75K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.55% | 152,474 | 265.30K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 95,862 | 166.80K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.12% | 33,086 | 57.57K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 29,297 | 50.98K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 22,655 | 39.42K | Oct 30, 2024 |